Blood test may spot breast cancer resistance before It's too late
NCT ID NCT06388122
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is looking at whether a blood test called DiviTum TKa can predict when hormone-receptor-positive, HER2-negative metastatic breast cancer stops responding to treatment. About 100 participants will give blood samples before and during their standard therapy. The goal is to find a pattern that signals resistance within 6 months, which could help doctors switch treatments sooner.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANATOMIC STAGE II BREAST CANCER AJCC V8 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Mayo Clinic in Florida
RECRUITINGJacksonville, Florida, 32224-9980, United States
Contact Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Virtual therapy may ease breast cancer treatment side effects
- Fasting during chemo: a new way to boost treatment?
- A gentle jog might be the key to better sleep for breast cancer survivors
- Can a Two-Drug attack shrink Hard-to-Treat breast cancer?
- Gut bacteria may fortify bones in breast cancer therapy
- Can a smart drug cross the Blood-Brain barrier to attack breast cancer metastases?